{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:34:39Z","timestamp":1792226079835,"version":"4.4.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["slas-discovery.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["SLAS Discovery"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.slasd.2025.100254","type":"journal-article","created":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T05:27:51Z","timestamp":1753594071000},"page":"100254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Off-target effects of oligonucleotides and approaches of preclinical assessments"],"prefix":"10.1016","volume":"35","author":[{"given":"Haiwen","family":"Ruan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3622-6412","authenticated-orcid":false,"given":"Dehu","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinjiang","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.slasd.2025.100254_bib0001","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40259-022-00549-3","article-title":"Therapeutic siRNA: state-of-the-art and Future perspectives","volume":"36","author":"Friedrich","year":"2022","journal-title":"BioDrugs"},{"issue":"6","key":"10.1016\/j.slasd.2025.100254_bib0002","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-024-00943-2","article-title":"Frameworks for transformational breakthroughs in RNA-based medicines","volume":"23","author":"Androsavich","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.slasd.2025.100254_bib0003","series-title":"Advances in nucleic acid therapeutics. drug discovery series","first-page":"474","article-title":"Preclinical and clinical drug-metabolism, pharmacokinetics and safety of therapeutic oligonucleotides","volume":"1","author":"Andersson","year":"2019"},{"issue":"1","key":"10.1016\/j.slasd.2025.100254_bib0004","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40291-021-00573-z","article-title":"Reduction of off-target effects of gapmer antisense oligonucleotides by oligonucleotide extension","volume":"26","author":"Yasuhara","year":"2022","journal-title":"Mol Diagn Ther"},{"issue":"2","key":"10.1016\/j.slasd.2025.100254_bib0005","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/bph.17302","article-title":"Mitigating off-target effects of small RNAs: conventional approaches, network theory and artificial intelligence","volume":"182","author":"Bereczki","year":"2025","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.slasd.2025.100254_bib0006","series-title":"PMDA: guideline for preclinical safety assessment of oligonucleotide therapeutics","year":"2020"},{"key":"10.1016\/j.slasd.2025.100254_bib0009","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1089\/nat.2020.0892","article-title":"Outcomes of the European Federation of Phar- maceutical Industries and Associations Oligonucleotide Working Group survey on nonclinical practices and regulatory expectations for therapeutic oligonucleotide safety assessment","volume":"31","author":"Tessier","year":"2021","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.slasd.2025.100254_bib0010","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1089\/nat.2020.0879","article-title":"Considerations of the Japanese Research Working Group for the ICH S6 & related issues regarding nonclinical safety assessments of oligonucleotide therapeutics: comparison with those of biopharmaceuticals","volume":"31","author":"Hirabayashi","year":"2021","journal-title":"Nucleic Acid Ther"},{"issue":"1","key":"10.1016\/j.slasd.2025.100254_bib0011","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/cells9010137","article-title":"RNA-based therapeutics: from antisense oligonucleotides to miRNAs","volume":"9","author":"Bajan","year":"2020","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.slasd.2025.100254_bib0012","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41467-018-02989-4","article-title":"Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity","volume":"9","author":"Janas","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.slasd.2025.100254_bib0013","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1089\/nat.2024.0072","article-title":"Assessing hybridization-dependent off-target risk for therapeutic oligonucleotides: updated industry recommendations","volume":"35","author":"Andersson","year":"2025","journal-title":"Nucleic Acid Ther"},{"issue":"1","key":"10.1016\/j.slasd.2025.100254_bib0014","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13059-019-1621-7","article-title":"Multiple-gene targeting and mismatch tolerance can confound analysis of genome-wide pooled CRISPR screens","volume":"20","author":"Fortin","year":"2019","journal-title":"Genome Biol"},{"issue":"11","key":"10.1016\/j.slasd.2025.100254_bib0015","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.1093\/nar\/gky397","article-title":"Identifying and avoiding off-target effects of RNase H-dependent antisense oligonucleotides in mice","volume":"46","author":"Hagedorn","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"10.1016\/j.slasd.2025.100254_bib0016","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.molcel.2019.12.029","article-title":"Directed RNase H cleavage of nascent transcripts causes transcription termination","volume":"77","author":"Lai","year":"2020","journal-title":"Mol Cell"},{"key":"10.1016\/j.slasd.2025.100254_bib0017","doi-asserted-by":"crossref","DOI":"10.1038\/srep30377","article-title":"Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides","volume":"6","author":"Kasuya","year":"2016","journal-title":"Sci Rep."},{"issue":"9","key":"10.1016\/j.slasd.2025.100254_bib0018","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.3390\/ijms25094809","article-title":"Antisense oligonucleotides (ASOs) in motor neuron diseases: a road to cure in light and shade","volume":"25","author":"Cantara","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"Pt 2","key":"10.1016\/j.slasd.2025.100254_bib0019","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.semcancer.2022.03.025","article-title":"RNA-binding proteins in regulating mRNA stability and translation: roles and mechanisms in cancer","volume":"86","author":"Li","year":"2022","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"10.1016\/j.slasd.2025.100254_bib0020","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-61666-3","article-title":"Introduction of sugar-modified nucleotides into CpG-containing antisense oligonucleotides inhibits TLR9 activation","volume":"14","author":"Yoshida","year":"2024","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.slasd.2025.100254_bib0021","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1007\/s13346-023-01361-4","article-title":"Innate immune regulations and various siRNA modalities","volume":"13","author":"Kaushal","year":"2023","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.slasd.2025.100254_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2023.100166","article-title":"Antisense oligonucleotide based therapeutics and its applications against bacterial infections","volume":"20","author":"Angrish","year":"2023","journal-title":"Med Drug Discov"},{"issue":"3","key":"10.1016\/j.slasd.2025.100254_bib0023","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nbt.3779","article-title":"Cellular uptake and trafficking of antisense oligonucleotides","volume":"35","author":"Crooke","year":"2017","journal-title":"Nat Biotechnol"},{"issue":"2","key":"10.1016\/j.slasd.2025.100254_bib0024","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1021\/bc200377d","article-title":"Cellular uptake and intracellular trafficking of antisense and siRNA oligonucleotides","volume":"23","author":"uliano","year":"2012","journal-title":"Bioconjug Chem"},{"issue":"1","key":"10.1016\/j.slasd.2025.100254_bib0025","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-61666-3","article-title":"Introduction of sugar-modified nucleotides into CpG-containing antisense oligonucleotides inhibits TLR9 activation","volume":"14","author":"Yoshida","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.slasd.2025.100254_bib0026","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/nbt1161","article-title":"Activation of the mammalian immune system by siRNA [J]","volume":"23","author":"Joao","year":"2005","journal-title":"Nat. Biotechnol."},{"issue":"6","key":"10.1016\/j.slasd.2025.100254_bib0027","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1089\/nat.2022.0033","article-title":"Early-stage identification and avoidance of antisense oligonucleotides causing species-specific inflammatory responses in Human volunteer peripheral blood mononuclear cells","volume":"32","author":"Burel","year":"2022","journal-title":"Nucleic Acid Ther"},{"issue":"4","key":"10.1016\/j.slasd.2025.100254_bib0028","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1089\/nat.2015.0598","article-title":"Comparative renal toxicopathology of antisense oligonucleotides","volume":"26","author":"Engelhardt","year":"2016","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.slasd.2025.100254_bib0029","unstructured":"Agarwal S., Moran L., Woldemariam S., et al. Mechanisms of rat hepatotoxicity of galnac-sirna conjugates. Alnylam Pharmaceuticals, Cambridge. USA."},{"issue":"5","key":"10.1016\/j.slasd.2025.100254_bib0030","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1093\/nar\/gkv1210","article-title":"Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts [J]","volume":"44","author":"Burel","year":"2016","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.slasd.2025.100254_bib0031","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41467-018-02989-4","article-title":"Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity [J]","volume":"9","author":"Janas","year":"2018","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.slasd.2025.100254_bib0032","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1093\/nar\/gkac539","article-title":"From bench to bedside: improving the clinical safety of GalNAc-siRNA conjugates using seed-pairing destabilization","volume":"50","author":"Schlegel","year":"2022","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"10.1016\/j.slasd.2025.100254_bib0033","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1177\/0192623315570341","article-title":"Scientific and Regulatory Policy Committee points-to-consider paper: drug-induced vascular injury associated with Nonsmall molecule therapeutics in preclinical development: part 2. Antisense oligonucleotides","volume":"43","author":"Engelhardt","year":"2015","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.slasd.2025.100254_bib0034","series-title":"Advances in nucleic acid therapeutics","first-page":"474","article-title":"CHAPTER 20 preclinical and clinical drug-metabolism, pharmacokinetics and safety of therapeutic oligonucleotides","author":"Andersson","year":"2019"},{"key":"10.1016\/j.slasd.2025.100254_bib0035","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1124\/dmd.121.000418","article-title":"Adverse Drug reactions and toxicity of the Food and Drug Administration-approved antisense oligonucleotide drugs","volume":"50","author":"Alhamadani","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.slasd.2025.100254_bib0036","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/0192623314551840","article-title":"Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist's perspective","volume":"43","author":"Frazier","year":"2015","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.slasd.2025.100254_bib0037","article-title":"Nephrotoxicity of marketed antisense oligonucleotide drugs","volume":"32","author":"Wu","year":"2022","journal-title":"Curr Opin Toxicol Dec"},{"key":"10.1016\/j.slasd.2025.100254_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114196","article-title":"Antisense drug discovery and development technology considered in a pharmacological context","volume":"189","author":"Crooke","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.slasd.2025.100254_bib0039","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.omtn.2019.11.020","article-title":"Identifying and avoiding tcDNA-ASO sequence-specific toxicity for the development of DMD Exon 51 skipping therapy","volume":"19","author":"Aupy","year":"2020","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.slasd.2025.100254_bib0040","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0022-3565(24)36667-4","article-title":"Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action","volume":"281","author":"Henry","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.slasd.2025.100254_bib0041","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1089\/nat.2015.0593","article-title":"Considerations for the characterization and interpretation of results related to alternative complement activation in monkeys associated with oligonucleotide-based therapeutics","volume":"26","author":"Henry","year":"2016","journal-title":"Nucleic Acid Ther"},{"issue":"4","key":"10.1016\/j.slasd.2025.100254_bib0042","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1089\/nat.2015.0584","article-title":"Effects of repeated complement activation associated with chronic treatment of Cynomolgus monkeys with 2\u2032-O-methoxyethyl modified antisense oligonucleotide","volume":"26","author":"Shen","year":"2016","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.slasd.2025.100254_bib0043","article-title":"Nephrotoxicity of marketed antisense oligonucleotide drugs","volume":"32","author":"Wu","year":"2022","journal-title":"Curr Opin Toxicol"},{"issue":"10","key":"10.1016\/j.slasd.2025.100254_bib0044","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1093\/nar\/gkaa299","article-title":"Phosphorothioate modified oligonucleotide-protein interactions","volume":"48","author":"Crooke","year":"2020","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"10.1016\/j.slasd.2025.100254_bib0045","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1182\/blood.V92.5.1617","article-title":"Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex","volume":"92","author":"Sheehan","year":"1998","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.slasd.2025.100254_bib0046","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1089\/nat.2015.0584","article-title":"Effects of repeated complement activation associated with chronic treatment of Cynomolgus monkeys with 2\u2032-O-methoxyethyl modified antisense oligonucleotide","volume":"26","author":"Shen","year":"2016","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.slasd.2025.100254_bib0047","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"10.1016\/j.slasd.2025.100254_bib0048","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/nat.2021.0071","article-title":"Acute neurotoxicity of antisense oligonucleotides after intracerebroventricular injection into mouse brain can Be predicted from sequence features","volume":"32","author":"Hagedorn","year":"2022","journal-title":"Nucleic Acid Ther"},{"issue":"12","key":"10.1016\/j.slasd.2025.100254_bib0049","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1016\/j.ymthe.2024.10.024","article-title":"Quantifying and mitigating motor phenotypes induced by antisense oligonucleotides in the central nervous system","volume":"32","author":"Moazami","year":"2024","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.slasd.2025.100254_bib0050","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s40291-020-00504-4","article-title":"Using RNA-seq to assess off-target effects of antisense oligonucleotides in Human cell lines","volume":"25","author":"Michel","year":"2021","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.slasd.2025.100254_bib0051","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-1-0716-1298-9_2","article-title":"Selection of chemical modifications in the siRNA seed region that repress off-target effect","volume":"2282","author":"Kobayashi","year":"2021","journal-title":"Methods Mol Biol"},{"issue":"18","key":"10.1016\/j.slasd.2025.100254_bib0052","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.3390\/plants12183235","article-title":"The hepatoprotective effects of Moringa oleifera against antiretroviral-induced cytotoxicity in HepG2 cells: a review","volume":"12","author":"Saki","year":"2023","journal-title":"Plants"},{"issue":"258","key":"10.1016\/j.slasd.2025.100254_bib0053","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.toxlet.2016.06.1127","article-title":"Cytotoxicity evaluation using cryopreserved primary human hepatocytes in various culture formats","volume":"6","author":"Richert","year":"2016","journal-title":"Toxicol Lett Sep"},{"issue":"4","key":"10.1016\/j.slasd.2025.100254_bib0054","doi-asserted-by":"crossref","DOI":"10.1002\/biot.70018","article-title":"Novel approach using real-time dynamic imaging analysis to monitor cellular apoptosis, viability, and cell density in CHO cell-based bioprocesses for monoclonal antibody production","volume":"20","author":"Corredor","year":"2025","journal-title":"Biotechnol J"},{"issue":"7","key":"10.1016\/j.slasd.2025.100254_bib0055","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1177\/0192623318792537","article-title":"The nonclinical safety profile of GalNAc- conjugated RNAi therapeutics in subacute studies [J]","volume":"46","author":"Maja","year":"2018","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.slasd.2025.100254_bib0056","unstructured":"FDA. Givosiran NDA Multi-disciplinary Review and Evaluation[EB\/OL]. (2019-11-20) [2025-07-18]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/212194Orig1s000TOC.cfm."},{"key":"10.1016\/j.slasd.2025.100254_bib0057","unstructured":"FDA. Leqvio NDA Multi-disciplinary Review and Evaluation[EB\/OL]. (2021-12-22) [2025-07-18]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/214012Orig1s000TOC.cfm."},{"key":"10.1016\/j.slasd.2025.100254_bib0058","unstructured":"FDA. Oxlumo NDA Multi-disciplinary Review and Evaluation[EB\/OL]. (2020-11-23) [2025-07-18]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/214103Orig1s000TOC.cfm."},{"key":"10.1016\/j.slasd.2025.100254_bib0059","unstructured":"FDA. AMVUTTRA NDA Multi-disciplinary Review and Evaluation[EB\/OL]. (2022-06-13) [2025-07-18]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/215515Orig1s000TOC.cfm."},{"key":"10.1016\/j.slasd.2025.100254_bib0060","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-1-61779-037-9_5","article-title":"Chemical modification of small interfering RNA","volume":"721","author":"Bramsen","year":"2011","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.slasd.2025.100254_bib0061","doi-asserted-by":"crossref","first-page":"5761","DOI":"10.1093\/nar\/gkq341","article-title":"A screen of chemical modifications identifies position-specific modification by UNA to most potently reduce siRNA off-target effects","volume":"38","author":"Bramsen","year":"2010","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"10.1016\/j.slasd.2025.100254_bib0062","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1538\/expanim.17-0150","article-title":"Comparative immunity of antigen recognition, differentiation, and other functional molecules: similarities and differences among common marmosets, humans, and mice","volume":"67","author":"Kametani","year":"2018","journal-title":"Exp Anim"},{"issue":"7","key":"10.1016\/j.slasd.2025.100254_bib0063","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1093\/nar\/gkz140","article-title":"Safety evaluation of 2\u2032-deoxy-2\u2032-fluoro nucleotides in GalNAc-siRNA conjugates","volume":"47","author":"Sutherland","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"10.1016\/j.slasd.2025.100254_bib0064","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021503","article-title":"siRNA off-target effects can be reduced at concentrations that match their individual potency","volume":"6","author":"Caffrey","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.slasd.2025.100254_bib0065","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s40291-020-00504-4","article-title":"Using RNA-seq to assess off-target effects of antisense oligonucleotides in human cell lines","volume":"25","author":"Michel","year":"2021","journal-title":"Mol Diagn Ther"},{"issue":"8","key":"10.1016\/j.slasd.2025.100254_bib0066","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071057","article-title":"A human in vitro whole blood assay to predict the systemic cytokine response to therapeutic oligonucleotides including siRNA","volume":"8","author":"Coch","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.slasd.2025.100254_bib0067","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3324\/haematol.2020.260059","article-title":"Sequence-specific 2\u2019-O-methoxyethyl anti- sense oligonucleotides activate human platelets through glycoprotein VI, triggering formation of platelet- leukocyte aggregates","volume":"107","author":"Slingsby","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.slasd.2025.100254_bib0068","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/978-1-4939-9670-4_15","article-title":"In vitro assessment of the hepatotoxicity potential of therapeutic oligonucleotides","volume":"2036","author":"Sewing","year":"2019","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.slasd.2025.100254_bib0069","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1007\/s00204-021-03062-8","article-title":"Nephrotoxic anti- sense oligonucleotide SPC5001 induces kidney injury biomarkers in a proximal tubule-on-a-chip","volume":"95","author":"Nieskens","year":"2021","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.slasd.2025.100254_bib0070","first-page":"17","article-title":"Palmitic acid conjugation enhances potency of tricyclo-DNA splice switching oligonucleotides","volume":"11","author":"Relizani","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.slasd.2025.100254_bib0071","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1089\/nat.2014.0491","article-title":"Mechanism of alternative complement pathway dysregulation by a phosphorothioate oligonucleotide in monkey and human serum","volume":"24","author":"Henry","year":"2014","journal-title":"Nucleic Acid Ther"},{"issue":"3","key":"10.1016\/j.slasd.2025.100254_bib0072","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10557-019-06919-4","article-title":"Phase 3 multicenter study of Revusiran in patients with hereditary transthyretin-mediated (hATTR) amyloidosis with cardiomyopathy (ENDEAVOUR)","volume":"34","author":"Judge","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.slasd.2025.100254_bib0073","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/978-981-13-8871-2_20","article-title":"Complement activation in progression of chronic kidney disease","volume":"1165","author":"Chen","year":"2019","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"10.1016\/j.slasd.2025.100254_bib0074","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nbt0410-295","article-title":"Safety signal dampens reception for mipomersen antisense","volume":"28","author":"Kling","year":"2010","journal-title":"Nat Biotechnol"}],"container-title":["SLAS Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2472555225000474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2472555225000474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T07:32:21Z","timestamp":1779867141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2472555225000474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":72,"alternative-id":["S2472555225000474"],"URL":"https:\/\/doi.org\/10.1016\/j.slasd.2025.100254","relation":{},"ISSN":["2472-5552"],"issn-type":[{"value":"2472-5552","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Off-target effects of oligonucleotides and approaches of preclinical assessments","name":"articletitle","label":"Article Title"},{"value":"SLAS Discovery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.slasd.2025.100254","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of Society for Laboratory Automation and Screening.","name":"copyright","label":"Copyright"}],"article-number":"100254"}}